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Abstract: Novel treatments for glioblastoma, the most common malignant primary brain tumor, are
urgently required. Type I interferons (IFN) are natural cytokines primarily involved in the defense
against viral infections, which may also serve a role in the control of cancer, notably in the suppression
of the cancer stem cell phenotype. TG02 is a novel orally available cyclin-dependent kinase 9 inhibitor
which induces glioma cell apoptosis without profound caspase activation, which is currently explored in
early clinical trials in newly diagnosed and recurrent glioblastoma. In the present study, human glioma-
initiating cell line models were used to explore whether IFN-฀ modulates the anti-glioma activity of
TG02. The present study employed immunoblotting to assess protein levels, several viability assays and
gene silencing strategies to assess gene function. Pre-exposure to IFN-฀ sensitized human glioma models
to a subsequent exposure to TG02. Combination treatment was associated with increased DEVD-amc
cleaving caspase activity that was blocked by the anti-apoptotic protein, BCL2. However, BCL2 did not
protect from the synergistic effects of IFN and TG02 on glioma cell growth. Furthermore, although IFN
strongly induced pro-apoptotic XIAP-associated factor (XAF) expression, disrupting XAF expression did
not abrogate the synergy with TG02. Consistent with that, caspase 3 gene silencing did not abrogate
the effects of TG02 or IFN-฀ alone or in combination. Finally, it was observed that IFN-฀ may indeed
modulate the effects of TG02 upstream in the signaling cascade since inhibition of RNA polymerase II
phosphorylation, a direct readout of the pharmacodynamic activity of TG02, was facilitated when glioma
cells were pre-exposed to IFN-฀. In summary, these data suggest that type I IFN may be combined with
TG02 to limit glioblastoma growth, but that the well characterized effects of IFN and TG02 on apoptotic
signaling are dispensable for synergistic tumor growth inhibition. Instead, exploring how IFN signaling
primes glioma cells for TG02-mediated direct target inhibition may help to design novel and effective
pharmacological approaches to glioblastoma.
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Abstract. Novel treatments for glioblastoma, the most common 
malignant primary brain tumor, are urgently required. Type 
I interferons (IFN) are natural cytokines primarily involved 
in the defense against viral infections, which may also serve 
a role in the control of cancer, notably in the suppression 
of the cancer stem cell phenotype. TG02 is a novel orally 
available cyclin-dependent kinase 9 inhibitor which induces 
glioma cell apoptosis without profound caspase activation, 
which is currently explored in early clinical trials in newly 
diagnosed and recurrent glioblastoma. In the present study, 
human glioma-initiating cell line models were used to explore 
whether IFN-β modulates the anti-glioma activity of TG02. 
The present study employed immunoblotting to assess protein 
levels, several viability assays and gene silencing strategies to 
assess gene function. Pre-exposure to IFN-β sensitized human 
glioma models to a subsequent exposure to TG02. Combination 
treatment was associated with increased DEVD-amc cleaving 
caspase activity that was blocked by the anti-apoptotic protein, 
BCL2. However, BCL2 did not protect from the synergistic 
effects of IFN and TG02 on glioma cell growth. Furthermore, 
although IFN strongly induced pro-apoptotic XIAP-associated 
factor (XAF) expression, disrupting XAF expression did not 
abrogate the synergy with TG02. Consistent with that, caspase 
3 gene silencing did not abrogate the effects of TG02 or 
IFN-β alone or in combination. Finally, it was observed that 
IFN-β may indeed modulate the effects of TG02 upstream in 
the signaling cascade since inhibition of RNA polymerase II 
phosphorylation, a direct readout of the pharmacodynamic 
activity of TG02, was facilitated when glioma cells were 
pre-exposed to IFN-β. In summary, these data suggest that 
type I IFN may be combined with TG02 to limit glioblastoma 
growth, but that the well characterized effects of IFN and 
TG02 on apoptotic signaling are dispensable for synergistic 
tumor growth inhibition. Instead, exploring how IFN signaling 
primes glioma cells for TG02-mediated direct target inhibi-
tion may help to design novel and effective pharmacological 
approaches to glioblastoma.
Introduction
Glioblastoma is the most common malignant intrinsic brain 
tumor in adults (1). These tumors are believed to originate 
from molecular genetic lesions in neuroglial stem or progen-
itor cells and can arise at any age, but the risk of developing 
glioblastoma increases with age (2). The WHO classification 
characterizes glioblastomas as glial tumors exhibiting the 
histopathological features of microvascular proliferation 
and necrosis which are characteristics of WHO grade IV 
tumors (3). Typical glioblastomas do not show mutations in the 
isocitrate dehydrogenase genes, but genetic alterations in three 
major pathways: The phosphoinositide 3-kinase (PI3K)/protein 
kinase B (AKT)/mammalian target of rapamycin (mTOR), 
the p53 and the retinoblastoma (RB) pathways; furthermore, 
tyrosine kinases such as epidermal growth factor receptor and 
c-MET mediate and maintain the malignant phenotype of 
glioblastoma (4).
There has been essentially no progress in the pharma-
cological therapy of this tumor since the introduction of 
temozolomide in 2005 (5,6). Notably targeted therapies have 
failed at least in unselected patient populations that were 
not pre-enriched for certain molecular markers (7). Type 
I interferons (IFN) have already been tested for potential 
anti-glioma activity in the early periods of cancer immuno-
therapy. IFN are endogenous cytokines that have a major role 
in combatting viral infections. Moreover, there is increasing 
interest in a role of type I IFN in suppressing tumor growth, 
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notably a role in negatively regulating the cancer stem cell 
phenotype (8). We and others have previously characterized 
profound anti-glioblastoma stem cell properties of type I 
IFN in vitro that involved suppression of sphere formation 
but relatively little induction of cell death. The failure of IFN 
to induced cell death was surprising since the IFN-induced 
transcriptional changes in glioma cells were predicted to 
favour activation of the intrinsic caspase-dependent cell 
death pathway (9,10). These promising cell culture data 
indicating efficacy of IFN against glioblastoma appear to 
be in conflict with the failure to confirm activity of type I 
IFN in clinical trials with human glioblastoma patients (11). 
Yet, interest in IFN signaling in glioblastoma persists and 
current efforts focus on integrating IFN into combined 
modality treatments.
TG02 is a novel orally available inhibitor of multiple 
cyclin-dependent kinases (CDK) that exhibits strong in vitro 
activity in glioma models while single agent activity in rodent 
glioma models remains moderate (12,13). TG02 is currently 
explored in clinical trials in recurrent and in newly diagnosed 
glioblastoma (NCT02942264, NCT03224104) (14). The 
present study sought to explore whether the combination of 
type I IFN with TG02 might exhibit synergistic activity and 
might be suitable to activate caspase-dependent cell death 
pathways in human glioma models in vitro.
Materials and methods
Reagents. Human IFN-β1a was provided by Biogen Inc. Stock 
solutions for in vitro experiments were prepared in 20 mM 
sodium acetate, pH 8.4, containing 150 mM arginine hydro-
chloride. TG02 was provided by Adastra. Staurosporine was 
purchased from AppliChem, acetyl-Asp-Glu-Val-Asp-7-ami
no-4-methyl coumarin (ac-DEVD-amc) and benzyloxycar-
bonyl‑Val‑Ala‑Asp (OMe)‑fluoromethylketone (zVAD‑fmk) 
were obtained from Bachem. ON-TARGET plus human siRNA 
SMART pool targeting human X-linked inhibitor of apoptosis 
protein (XIAP)-associated factor (XAF)-1 or caspase 3 was 
purchased from Dharmacon.
Cell culture. The human long-term cell line, LN-229, and 
the human glioma-initiating cell lines (GIC), T-325, ZH-161, 
S-24, and ZH-305, and their sensitivity to TG02 have 
been described in detail (12). LN-229 cells were cultured 
in Dulbecco's modified Eagle's medium supplemented 
with 10% fetal calf serum (Invitrogen) and 1% glutamine 
(Invitrogen). After approval of the local ethics committees 
of the procedure and after obtaining informed consent 
from patients, GIC were isolated from freshly resected 
tumors using the Papain Dissociation System (Worthington 
Biochemical Corporation). GIC were maintained in 
Neurobasal Medium (NB) with B-27 supplement (20 µl/ml) 
(Thermo Fisher Scientific, Inc.), L‑glutamine (10 µl/ml), 
fibroblast growth factor-2 and epidermal growth factor 
(20  ng/ml each; Peprotech) and penicillin/streptomycin 
(pen-strep, Sigma-Aldrich/Merck). The GIC were studied 
within a range of maximum passages of 40-50. All cells 
were sent for short tandem repeat analysis (DSMZ) and 
are regularly tested for mycoplasma contamination, last in 
November 2018.
Acute growth inhibition assay. After seeding cells and after 
a recovery time of 24 h in complete medium, the cells were 
exposed to TG02 for acute growth inhibition assays for 72 h 
(high seeding density, 1.5x104 cells for LN-229 or 104 cells 
for GIC per well) or for the determination of clonogenic 
survival (low seeding density, 50 cells for LN-229 or 150 cells 
per well for GIC) for more than ten days in 96 well plates. 
Human IFN-β1a was added 24 h prior to TG02 exposure and 
maintained throughout the experiment as indicated. Metabolic 
activity was assessed by MTT assay (Sigma Aldrich).
RT‑qPCR. For gene expression analyses, total mRNA was 
extracted after 24 h incubation in serum-free medium. Gene 
expression was determined by the Real-Time PCR System 
QuantStudio 6 using PowerUp SYBR™ Green Master Mix 
(Thermo Fisher Scientific, Inc.) using primers at optimized 
concentrations. Relative quantification was calculated using 
the ΔCT-method (15) and specific target gene expression 
was normalized to the housekeeping genes hypoxanthine 
phosphoribosyltransferase 1 (HPRT1) or ADP-ribosylation 
factor 1 (ARF1). The following human-specific primers 
were used: IFNAR2 (Bio-Rad; qHsaCED0045841), XAF-1 
(Bio-Rad; qHsaCED0045841), ARF1 (forward 5'-GAC CAC 
GAT CCT CTA CAA GC-3', reverse 5'-TCC CAC ACA GTG AAG 
CTG-3'), caspase 3 (forward 5'-TGG AGA TCA GCT CCC GAG 
ATG-3', reverse 5'-ATT GCC CAC AGC CAC TCT G-3'), HPRT1 
(forward 5'-TGA GGA TTT GGA AAG GGT GT-3', reverse 
5'-AGC ACA CAG AGG GCT ACA A-3'), IFNAR1 (forward 
5'-TAT GCT GCG AAA GTC TTC TTG AG-3', reverse 5'-TCT 
TGG CTA GTT TGG GAA CTG TA-3') and myxovirus resis-
tance protein A (MxA) (forward 5'-TGG AGA TCA GCT CCC 
GAG ATG-3', reverse 5'-ATT GCC CAC AGC CAC TCT G-3') 
(all Microsynth).
Immunoblotting. Immunoblot analysis was performed as 
described (12). Whole cell lysates were prepared using 
radioimmunoprecipitation assay (RIPA) buffer [10 mM Tris 
pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% 
SDS] supplemented with 1% complete protease inhibitor mix 
(Roche Diagnostics) and phosphatase inhibitor cocktails 1 
and 2 (Sigma-Aldrich), and protein levels were determined 
by Bradford assay. After loading equal protein amounts, 
SDS-PAGE (10% acrylamide gels) was performed under 
reducing conditions followed by protein transfer to nitrocel-
lulose membranes. To avoid unspecific antibody binding, 
membranes were blocked in Tris-buffered saline containing 
0.1% Tween 20 and 5% skim milk or 5% bovine serum 
albumin. For primary antibody incubation the following anti-
bodies were used: Rabbit anti-IFNAR1 (LifeSpan BioSciences 
Inc., Seattle, WI, LS-C185508), mouse anti-MxA hybridoma 
supernatant (provided by J. Pavlovic, Zurich, Switzerland, 
clone 143), rabbit anti-XAF-1 (Santa Cruz Biotechnology; 
sc-19194), rabbit anti-caspase 3 (Santa Cruz Biotechnology; 
sc-9662), rabbit anti-phosphorylated-Rpb1 (RNAPII) (Cell 
Signaling Technology, 13499), rabbit anti-MCL-1 Cell 
Signaling Technology; 5453), rabbit anti-c-MYC (Cell 
Signaling Technology; 5605), rabbit anti-CDK9 (Santa 
Cruz Biotechnology; sc-13130) or rabbit anti-β-actin (Santa 
Cruz Biotechnology; sc1616). As secondary antibodies 
Amersham ECL sheep anti-mouse IgG-HRP (GE Healthcare 
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Lifesciences; NA931V) or goat anti-rabbit IgG-HRP (Santa 
Cruz Biotechnology; sc-2004) were used.
Flow cytometry. Flow cytometry was performed according to 
standard protocols using phycoerythrin (PE)-conjugated mono-
clonal mouse anti-human IFNAR2 (PBL Assay Science;  clone 
MMHAR-2, 10 µg/ml) or PE-conjugated mouse IgG1κ isotype 
control (BD Biosciences; clone MOPC-21, 10 µg/ml). Induction 
of cell death was analyzed using annexin V (AnxV) (BioLegend) 
and propidium iodide (PI) (Sigma-Aldrich) staining. Cells 
were washed with annexin buffer (10 mM HEPES, 140 mM 
NaCl, 2.5 mM CaCl2, pH 7.4) and stained with 5 µl AnxV 
and 5 µl PI [50 µg/ml] for 15 min at room temperature in the 
dark. Staurosporine was used as positive control for apoptosis. 
Fluorescence intensity was recorded using a BD FACS Verse 
flow cytometer (BD Biosciences). Data (10,000 events per 
condition) were analyzed and median fluorescent intensities 
were calculated using FlowJo Version 10.0.7 (Tree Star).
Caspase activity assay. After exposure to TG02 or IFN-β1a 
alone or in combination in the absence or presence of 
zVAD-fmk, the cells were lysed with lysis buffer followed 
by incubation with the fluorescent substrate Ac‑DEVD‑amc 
[6.25 µM]. Measurement of DEVD-amc cleaving activity 
was performed using a Tecan Infinite M200 Pro plate reader 
(Tecan Trading AG) (480 nm emission; 360 nm excitation (12).
Figure 1. IFN-β sensitizes human glioma cells to TG02. (A and E) LN-229, (B and F) ZH-161, (C and G) ZH-305 or (D and H) S-24 cells were pre-exposed or 
not to IFN-β at 100 or 1,000 IU/ml for LN-229 or 10 or 100 IU/ml for the three GIC models for 24 h and then exposed to increasing concentrations of TG02 
in 72 h (A-D) acute growth inhibition or (E-H) clonogenic survival assays. Data are presented as mean percentages and standard error of the mean (n=3) of 
metabolic activity in a.u. relative to vehicle-treated control. *Synergy between TG02 and 100 IU/ml IFN-β in LN-229 or 10 IU/ml IFN-β in GIC. +Synergy 
between TG02 and 1,000 IU/ml IFN-β in LN-229 or 100 IU/ml IFN-β in GIC. a.u., arbitrary units; GIC, glioma-initiating cell; IFN, interferon.
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Transfection. For transient gene silencing, cells were trans-
fected at 20 µM of specific or scramble control small interfering 
(si) RNA by electroporation. Control or ON-TARGET plus 
siRNA SMARTpool were purchased from Dharmacon 
(caspase 3, L-004307-00-0005; xaf, L-004357-00-0005). At 
72 h post transfection, samples were treated with IFN-β1a or 
TG02 or both as indicated and processed for further treatment. 
For stable gene overexpression, cells were transfected with the 
sequence‑verified human bcl‑2/pcDNA3 plasmid (Addgene 
no. 19279) using the X-tremeGENE™ HP DNA Transfection 
Reagent. G418 sulfate was used for selection of clones with 
transgene expression (12).
Statistical analysis. Data are representative of experiments 
performed two to three times with similar results. Statistical 
analysis was performed using GraphPad Prism 5 or 7 software. 
Statistical significance was assessed using either two‑sided 
unpaired and paired Student's t-test or one-way ANOVA 
with Tukey's post hoc test for multiple comparison analysis. 
Quantitative data are represented as mean ± standard devia-
tion or standard error of the mean. P<0.05 was considered to 
indicate a statistically significant difference. Synergy was 
assessed using the fractional product method (16) and differ-
ences exceeding 10% of observed versus predicted (additive) 
effect were considered to indicate synergy.
Results
IFN‑β promotes TG02‑induced cell death. The expression 
of IFN-α/β receptors 1 and 2 in the human glioma cell 
line models used here and their uniform responsiveness to 
IFN-β in terms of MxA gene induction have been partially 
published (10,17) and are summarized in Fig. S1. Growth 
inhibitory effects of TG02 alone in the cell line models 
studied here have also been characterized (12). We first 
explored whether pre-exposure to IFN-β sensitized glioma 
cells to TG02 in short-term growth inhibition or clonoge-
nicity respectively spherogenicity assays. GIC were exposed 
to lower concentrations of IFN-β than the LN-229 long-term 
cell line because of the higher intrinisic sensitivity to IFN-β 
of GIC (10). We noted strong sensitization by IFN-β to 
TG02 in LN-229 and S-24 cells in acute growth inhibition 
assays and in S-24 cells in spherogenicity assays and largely 
additive effects in both assays in the other model systems 
(Fig. 1A-H). Synergistic induction of cell death by IFN-β 
and TG02 in LN‑229 cells was confirmed by AnxV/PI flow 
cytometry (Fig. 2).
Synergistic induction of caspase activation does not mediate 
synergistic growth inhibition by IFN‑β and TG02. We had 
previously observed that exposure to IFN-β induced changes 
in gene expression, notably induction of xaf expression, 
predicting enhanced vulnerability to caspase-dependent 
apoptosis (10) and that TG02 alone induces largely 
caspase-independent apoptosis (12). Indeed, pre-exposure 
of LN-229 cells to IFN-β facilitated processing of caspase 
3 in response to TG02 as confirmed by immunoblot, albeit 
only to a minor degree compared with exposure to stauro-
sporine which was used as a positive control (18) (Fig. 3A). 
Facilitation of induction of DEVD-amc-cleaving caspase 
activity by pre-exposure to IFN-β was confirmed by a fluo-
rimetric assay. Specificity was confirmed by demonstrating 
the abrogation of this caspase activity by the broad spectrum 
caspase inhibitor, zVAD-fmk, under all conditions (Fig. 3B). 
Similarly, BCL-2 gene transfer into LN-229 cells abrogated 
the promotion of caspase activation induced by the combi-
nation of IFN-β and TG02, again using staurosporine as a 
positive control (Fig. 3C). We have previously reported that 
BCL-2 moderately attenuates TG02-induced cell death, 
likely in a caspase-independent manner since zVAD-fmk 
had no such effect except for high TG02 concentrations in 
selected models (12). Here we report that neither zVAD-fmk 
Figure 2. IFN-β sensitizes human glioma cells to TG02. LN-229 cells were stimulated for 72 h with TG02 (100 nM) after being pre-exposed to IFN-β 
(1,000 IU/ml) or not. (A) Cells were then subjected to AnxV/PI flow cytometry. (B) Proportional distribution of AnxV/PI fractions (AnxV/PI +/+ in black, 
AnxV/PI +/-in light grey, AnxV/PI-/+ in dark grey, AnxV/PI -/-in white) are indicated as bar graphs. AnxV, annexin V; PI, propidium iodide; IFN, interferon.
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nor BCL‑2 interfered specifically with the sensitizing prop-
erties of IFN-β for TG02-induced cell death (Fig. 3D and E). 
This challenges the view that the enhanced caspase activity 
demonstrated in Fig. 3A-C was responsible for synergistic 
growth inhibition.
Neither xaf nor caspase 3 gene silencing block IFN‑β induced 
sensitization to TG02. To determine in more depth whether 
caspase-dependent apoptotic signalling mediates the synergy 
of IFN-β and TG02, we explored whether xaf induction or 
expression of caspase 3 were required for IFN-β-mediated 
Figure 3. IFN-β promotes DEVD-amc-cleavage activity induced by TG02. (A) Caspase 3 processing was monitored in LN-229 cells pre-exposed or not to IFN-β 
(1,000 IU/ml) for 24 h and then treated with TG02 (50 nM) in the absence or presence of IFN-β for another 24 h. (B) LN-229 cells were pretreated or not with 
IFN-β (100 or 1,000 IU/ml) for 24 h and then exposed to TG02 in the absence or presence of zVAD‑fmk (100 µM) for another 24 h prior to fluorimetric determi-
nation of DEVD-amc cleavage. (C) A similar experiment was conducted to compare the effects of IFN-β and TG02 and their combination in bcl‑2-transfected 
versus control transfected cells. In (B) and (C), stauro treatment for 24 h was used as a positive control. (D) LN-229 cells were treated as in Fig. 1A, but 
co-exposed to zVAD-fmk (100 µM) during TG02 exposure. (E) Bcl‑2-transfected vs. control transfected LN-229 cells were pretreated or not with IFN-β (100 or 
1,000 IU/ml) for 24 h and then exposed to TG02. Metabolic activity was assessed at 72 h by MTT assay. Casp 3, caspase 3; IFN, interferon; stauro, staurosporine; 
ac‑DEVD‑amc, acetyl‑Asp‑Glu‑Val‑Asp‑7‑amino‑4‑methyl coumarin; zVAD‑fmk, benzyloxycarbonyl‑Val‑Ala‑Asp‑fluoromethylketone; a.u., arbitrary units.
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Figure 4. IFN-β-mediated sensitization does not require XAF-1 or caspase 3. (A) XAF-1 protein levels were determined with or without IFN-β1a stimulation 
(1,000 IU/ml) for 24 h started at 72 h after electroporation to induce XAF-1 silencing in ZH-161 cells. (B) ZH-161 were pretreated or not with IFN-β at 10 or 
100 IU/ml for 24 h and then exposed to increasing concentrations of TG02. Metabolic activity was assessed after >10 days by MTT assay. (C) Caspase 3 gene 
silencing in ZH-161 cells assessed by immunoblot at 72 h, maintained in the presence of IFN-β [(1,000 IU/ml) for 24 h]. β-actin served as loading control. 
(D) Control-transfected or caspase 3-silenced ZH-161 cells treated as in (B). XAF, XIAP-associated factor; si, small interfering RNA; ctr, control; IFN, 
interferon; Casp3, caspase 3; a.u., arbitrary units; scr, scrambled control.
Figure 5. IFN-β facilitates TG02-induced inhibition of RNA polymerase II phosphorylation. Levels of pRNAPII, MCL-1, c-MYC and CDK9 were determined 
in LN-229 cells pretreated or not with IFN-β (1,000 IU/ml) for 24 h and then exposed to TG02 (100 nM) for 9, 24 or 72 h. β-actin served as loading control. 
pRNAPII, phosphorylated RNA polymerase II; ctr, control; IFN, interferon.
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sensitization to TG02. XAF is a previously identified IFN‑β 
response gene in human glioma cells including GIC (10) 
(Fig. S2A). We silenced xaf expression (Fig. S2B) which led 
to a strong reduction of XAF protein in response to IFN-β 
(Fig. 4A). However, depletion of XAF did not abrogate the 
sensitization of glioma cells to TG02 mediated by pre- exposure 
to IFN-β (Fig. 4B). Similarly, depletion of caspase 3 failed to 
affect the activity of this combination (Fig. 4C and D). We 
had previously observed features of senescence in one of two 
long-term glioma cell lines chronically exposed to TG02 (12). 
Accordingly, we determined senescence-associated 
β-galactosidase activity in two GIC models upon exposure to 
IFN-β or TG02 or both, using irradiation at 20 Gy as a positive 
control (19). S-24 cells stimulated with IFN-β or TG02 showed 
no increase in β-galactosidase activity whereas co-treatment 
did, but no such effect was seen in ZH-161 cells (Fig. S3).
IFN‑β facilitates direct TG02 target inhibition. Altogether 
these data indicated that the synergistic growth inhibition medi-
ated by pre-exposure to IFN-β followed by TG02 treatment 
might operate further up-stream, prior to the cell death 
pathways involving caspase inhibition or senescence. Indeed, 
immunoblot analyses allowed to demonstrate a time-depen-
dent suppression of RNA polymerase II phosphorylation by 
TG02 that was facilitated in glioma cells pre-exposed to 
IFN-β. Yet, the TG02-induced decreases of two major putative 
down-stream effectors of TG02, MCL-1 and c-MYC, were not 
enforced by IFN-β. In contrast, the protein levels of CDK9, the 
bona fide main target of TG02 and the kinase responsible for 
RNA polymerase II phosphorylation, were decreased by TG02 
alone and more so by the combination, at 72 h (Fig. 5).
Discussion
Effective pharmacological treatment options for glioblas-
toma have not been developed since the introduction of 
temozolomide in 2005 (5,6). Immunotherapy may have failed 
because glioblastomas are currently considered as lympho-
cyte-depleted or cold tumors (20). Targeted therapy has not 
been successful because glioblastoma in most instances, if not 
all, is not a single pathway-driven disease (7). This provides 
space for the development of innovative, more broadly acting 
anti-cancer agents in glioblastoma. A prominent example 
currently explored in a pivotal trial is the proteasome inhibitor, 
marizomib (NCT03345095). Another example is TG02, an 
orally available inhibitor of multiple CDK with good blood 
brain barrier penetration (NCT03224104). This drug has 
shown promising single agent activity at least in cell culture 
models (12,13).
We report that pre-exposure to type I interferon sensitizes 
human glioma models including GIC cultures to subsequent 
exposure to TG02, both in acute growth inhibition and in 
clonogenic survival assays (Fig. 1). We hypothesized that this 
synergy was related to the promotion of caspase-dependent 
apoptosis since IFN-β induces a shift in gene expression that 
should facilitate caspase-mediated cell death (10). Furthermore, 
TG02 alone is not a potent activator of the caspase-dependent 
cell death pathway, but activates alternative death path-
ways (12). Consistent with the expectation, immunoblot and 
caspase activity assays confirmed synergy in promoting 
caspase activation when IFN-β and TG02 were combined. 
Consistent with a mitochondrial type of caspase-mediated 
cell death, overexpression of BCL2 was protective (Fig. 3). 
A likely candidate promoting synergistic cell death was the 
proapoptotic protein, XAF1, which is highly inducible by type 
I interferon (10). Yet, a role of XAF1 in mediating synergistic 
cell death induction was excluded by XAF gene silencing. 
Further, somewhat unexpectedly, gene silencing of caspase 3 
did not abrogate the synergy of type I interferon and TG02 
either, and, expectedly, also not the activity of either agent 
administered alone (Fig. 4). 
Finally, we reconsidered that potentially synergy might 
operate more up-stream at the level where TG02 proximately 
triggers the cell death cascade. Indeed, immunoblot confirmed 
that there was a time-dependent decrease in the phosphoryla-
tion of RNAPII which was greatly facilitated by pre-exposure 
to IFN-β (Fig. 5). This loss of pRNAPII is predicted in 
response to TG02 since RNAPII is phosphorylated by CDK9, 
the principal target of TG02. That total CDK9 protein was 
also decreased, points to cdk9 being one of the genes with 
short-lived expression that is subject to TG02-induced 
transcriptional perturbations. Exploring how IFN signaling 
primes glioma cells for TG02-mediated direct target inhibi-
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